Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by PTBaileyon Apr 08, 2022 9:55am
104 Views
Post# 34587500

Claritas Pharmaceuticals approved to list on the OTCQB

Claritas Pharmaceuticals approved to list on the OTCQB
  • Claritas Pharmaceuticals (CLAS) has obtained approval from the OTC Markets Group to list its common shares on the OTCQB under the ticker symbol CLAZF
  • The company will continue to trade on the TSXV under the symbol CLAS
  • The OTCQB uplisting will make the company accessible to a much broader range of U.S. investors and brokers
  • Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
  • Claritas Pharmaceuticals, Inc. (CLAS) opened trading at $0.17 per share

Claritas Pharmaceuticals (CLAS) has obtained approval to list its common shares on the OTCQB under the ticker symbol CLAZF.

Robert Farrell, the company’s President and CEO commented on the news.

“We are very pleased to report that we have met all requirements and have been accepted by OTC Markets to up-list to the OTCQB tier for trading. We undertook the stringent qualification process for the OTCQB listing because we believe that trading on the OTCQB tier will bring added value to our shareholders. The OTCQB listing will elevate our profile within the investment community and is consistent with our long-term strategy to introduce the Company to a broader investor audience in the U.S. This upgrade is a significant milestone and a step toward the NASDAQ listing that we anticipate will occur next year.”

Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.

Claritas Pharmaceuticals, Inc. (CLAS) opened trading at $0.17 per share.

<< Previous
Bullboard Posts
Next >>